Lymphatic Interventions · IR Playbook

Lymphatic Embolization for Chyluria (-)

Lymphatic embolization for chyluria is a targeted percutaneous treatment of an abnormal communication between retroperitoneal or renal hilar lymphatics and the urinary collecting system. Intranodal lymphangiography identifies the uro-lymphatic fistula, followed by direct interstitial or retrograde trans–thoracic duct catheterization and embolization. Published evidence is limited to small series and case reports, but targeted fistula occlusion can produce durable cessation of chyluria while avoiding renal hilar lymphatic disconnection surgery.

Learning objectives

• Confirm true chyluria and localize the affected collecting system before intervention
• Recognize uro-lymphatic reflux and thoracic duct outflow obstruction on lymphatic imaging
• Select between direct interstitial and retrograde trans–thoracic duct fistula embolization
• Prevent non-target NBCA migration into the thoracic duct, systemic veins and urinary collecting system

Indications

• Persistent or recurrent chyluria despite dietary and cause-directed conservative treatment
• Clinically significant chyluria causing weight loss, hypoproteinemia, nutritional deficiency, immunologic compromise or recurrent clot retention
• Refractory chyluria after failed or recurrent renal pelvic instillation sclerotherapy
• Demonstrated renal-lymphatic or pyelolymphatic fistula suitable for targeted embolization
• Recurrent chyluria after prior lymphatic intervention when a persistent or new fistulous channel is identified

Relative contraindications

• Uncorrected coagulopathy or thrombocytopenia
• Active urinary or systemic infection
• Absence of a safe percutaneous or transvenous access route
• Uncertain diagnosis or laterality
• Diffuse lymphatic abnormality without an identifiable target
• Severe allergy to required contrast agents that cannot be adequately mitigated

Equipment

• High-frequency linear ultrasound transducer for inguinal lymph-node access
• 21–25G echogenic needles for bilateral intranodal lymphangiography
• Ethiodized oil for fluoroscopic lymphangiography
• 21G Chiba needle for cisterna chyli or retroperitoneal lymphatic puncture
• 0.014 inch and 0.018 inch hydrophilic guidewires; a 300 cm wire may be required for snaring and through-and-through access
• Approximately 2.0–2.7 Fr microcatheter compatible with the selected lymphatic wire
• Venous access set, 4–6 Fr sheath and snare when retrograde thoracic duct catheterization or wire externalization is planned
• Low-profile balloon catheter for temporary thoracic duct or lymphovenous-junction protection when required
• NBCA and ethiodized oil with nonionic preparation accessories
• 5% dextrose for microcatheter flushing and flow protection during NBCA delivery
• Detachable or pushable microcoils for selected high-flow or discrete channels
• Digital-subtraction fluoroscopy with cone-beam CT capability when available

Procedure steps

1. Confirm true chyluria, determine the affected side and review MR lymphatic imaging, cystoscopy or retrograde pyelography. Plan both the primary target and a rescue route if the fistula cannot be accessed directly.Pearl: Visible milky urine may be intermittent; urinary chylomicrons or triglycerides support the diagnosis when the urine is temporarily clear.
2. Under ultrasound, position a 21–25G needle within the parenchyma of one inguinal lymph node on each side. Confirm stable intranodal position with a small test injection while avoiding capsular extravasation.
3. Inject ethiodized oil slowly under intermittent fluoroscopy and follow pelvic and lumbar lymphatics toward the cisterna chyli and thoracic duct. Identify refluxing channels directed toward the renal hilum and opacification of the renal collecting system.Pearl: Correlate the fistulous side with cystoscopic ureteric efflux because bilateral or crossing lymphatic channels can occur.
4. Evaluate thoracic duct caliber, flow and drainage across the lymphovenous junction. Stasis, terminal obstruction or extensive collateralization suggests elevated central lymphatic pressure and may influence whether decompression is added to fistula embolization.
5. For a safely approachable opacified lumbar channel or node, use direct interstitial puncture. If no safe direct target exists, obtain antegrade or retrograde thoracic duct access and navigate a microcatheter selectively into the renal-directed fistulous branch.Pearl: Targeted branch catheterization limits unnecessary embolization of normal lymphatic pathways.
6. Perform very gentle contrast injection through the needle or microcatheter to confirm communication with the renal lymphatic plexus and collecting system. Define the flow direction, target volume and potential escape into the thoracic duct or systemic veins.
7. Position the catheter as close to the fistula as safely possible. When reflux toward the thoracic duct is likely, use temporary balloon occlusion, a second-catheter 5% dextrose flush or another controlled-flow technique to protect the central thoracic duct.Pearl: Balloon or dextrose protection is an adjunct; it does not compensate for an unstable or excessively proximal embolic position.
8. Flush the delivery catheter with 5% dextrose and inject NBCA–ethiodized oil under continuous fluoroscopy. Published cases used mixtures around 1:4 to 1:5, but dilution must be adjusted to flow, catheter-to-target distance and desired penetration. Coils may be added for a discrete high-flow channel or to create a scaffold.
9. Repeat a gentle control injection from an appropriate proximal position. Confirm exclusion of the renal-lymphatic fistula, preservation of non-target central lymphatic drainage and absence of embolic migration.Pearl: The desired endpoint is fistula occlusion, not routine complete thoracic duct embolization.
10. Remove lymphatic and venous access devices, obtain hemostasis and inspect all puncture sites. Monitor for abdominal or flank pain, hematuria, urinary obstruction, respiratory symptoms and access-site bleeding.

Complications

• Transient pain, fever or inflammatory reaction
• Access-site bleeding or retroperitoneal hematoma
• Infection, urinary tract infection or sepsis
• Non-target NBCA embolization into the thoracic duct or systemic veins
• NBCA migration into the urinary collecting system with obstruction
• Iatrogenic lymphatic obstruction or new chylous leak
• Persistent or recurrent chyluria

Exam pearls

• Target the renal-lymphatic fistula, not the entire thoracic duct.
• Urinary chylomicrons or triglycerides distinguish true chyluria from other causes of cloudy urine.
• Cystoscopy helps establish laterality by demonstrating milky efflux from the involved ureteric orifice.
• Thoracic duct obstruction can increase lymphatic pressure and drive reflux into renal lymphatics, but it is not present in every patient.
• Direct interstitial and retrograde trans–thoracic duct routes are complementary rather than competing techniques.
• Balloon protection or a second-catheter 5% dextrose flush can reduce reflux of NBCA into the central thoracic duct.
• There is currently no standardized society guideline or validated universal NBCA dilution for chyluria embolization.

Viva questions

What is the anatomical lesion treated during embolization for chyluria?

The target is an abnormal communication between refluxing renal hilar or retroperitoneal lymphatics and the urinary collecting system, termed a renal-lymphatic, pyelolymphatic or uro-lymphatic fistula.

How do you confirm that milky urine is truly chyluria?

Demonstration of urinary chylomicrons is confirmatory, and urinary triglycerides provide a practical biochemical test. Phosphaturia, pyuria and lipiduria are important mimics.

What are the two principal access strategies for fistula embolization?

The fistula may be treated by direct interstitial puncture of an opacified lumbar lymphatic channel or node, or by selective retrograde catheterization through the thoracic duct.

Why may a balloon be placed in the thoracic duct during interstitial embolization?

Temporary balloon occlusion reduces reflux of NBCA into the thoracic duct and systemic venous circulation while directing the embolic toward the renal-lymphatic fistula.

What is the correct embolization endpoint?

The fistulous renal-directed lymphatic branch should be occluded with no further collecting-system opacification and without significant embolic migration into the thoracic duct, systemic veins or urinary tract.

Should the thoracic duct itself be routinely embolized for chyluria?

No. The preferred target is the renal-lymphatic fistula. A patent thoracic duct should be preserved, while a demonstrated central obstruction may require individualized balloon angioplasty or stenting rather than empirical duct embolization.

Why can chyluria recur after technically successful treatment?

Recurrence may result from incomplete target penetration, recruitment of collateral renal lymphatics or persistent or recurrent thoracic duct outflow obstruction.

References